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This review will discuss the emerging need for BRS, the theoretical advantages of this new technology over current generation metallic DES and review the status of the currently available BRS. In addition, we will discuss the ideal duration of bioresorption, the proven and potential clinical benefits, and future perspective of this rapidly progressing technology.
The Emerging Need for Fully Bioresorbable Scaffold:
Historical Perspective
Invention of balloon angioplasty in 1977 by Andreas Gruntzig was a huge leap forward in the treatment of obstructive coronary artery disease, and was undoubtedly the 1st revolution in interventional cardiology. However, the mode of treatment was limited by risks of acute occlusion in the treated vessel as well as frequent restenosis, which occurred in approximately 30% to 40% of lesions after angioplasty. 7, 8 Restenosis after balloon angioplasty was essentially caused by constrictive remodeling, 9,10 and to a lesser extent by elastic recoil 11 and the neointimal hyperplastic healing response, 12-14 whilst in some cases late regression of narrowing in the dilated segment could potentially occur. 15 The advent of bare metal stenting, and the landmark BENESTENT and STRESS trials have established bare metal stents (BMS) as the 2nd revolution in interventional cardiology. 16, 17 This technology resolved the acute issues of the acute vessel occlusion by sealing the dissection flaps, and also tackled constrictive remodeling, with a halving of the subsequent restenosis rates. 16 However, since the vessel was left caged with metal post stenting, late luminal enlargement and advantageous vascular remodeling could no longer occur.
To solve the issue of in-stent restenosis, metallic DES were subsequently conceived, with the first 45 patients implanted with sirolimus-eluting Bx velocity stents being demonstrated to have negligible neointimal hyperplasia. 18 Metallic DES were thus dubbed the 3rd revolution in interventional cardiology. Both large-scale randomized trials and all-comer registries have shown excellent results in terms of the need for repeat revascularization. 19, 20 However, this early enthusiasm with metallic DES has been tempered in recent years by widespread concerns regarding the safety of DES with respect to acute, late and very late stent thrombosis. Registries of all-comers treated with DES demonstrated rates of late stent thrombosis of 0.53% per year, with a continued increase to 3% over 4 years. 21, 22 In patients with complex multivessel disease, the rate of combined definite, probable and possible stent thrombosis was as high as 9.4% at 5 years ONUMA Y et al.
and accounted for 32% of MACE events. 23 Furthermore, vasomotion testing revealed abnormal vasoconstriction responses to acetylcholine of the segments distal to the first-generation DES, suggesting that the structure and function of the endothelium remained abnormal after implantation of DES. 24, 25 Following numerous publications 26-28 suggesting an increased safety risk associated with DES, extensive research was conducted in an attempt to elucidate the causes of late stent thrombosis. The early cessation of dual antiplatelet therapy has consistently been shown to be the most significant independent predictor of stent thrombosis. 29, 30 Histopathologic studies have shown that the first-generation DES were associated with delayed re-endothelialization, localized vascular inflammation, thrombogenic reactions, and impaired functionality, which may have been caused by a hypersensitivity reaction to the presence of a permanent polymer. 31-33 These concerns made evident that a new approach was required to coronary stenting, which would be free from the long-term safety concerns but without compromising the beneficial low restenosis rates associated with metallic DES.
Although the use of a metallic DES without a polymer offers possible solutions, 34-36 the most definite solution is perhaps a scaffolding device that is fully biodegradable, and does not leave any struts behind after temporary scaffolding and drug elution has occurred. This provides the rationale for BRS, which is perceived as potentially the 4th revolution in interventional cardiology.
Fully Bioresorbable Scaffold: The Potential
Advantages and Technical Challenges BRS can potentially fulfil the requirements of the ideal scaffolding function in the treatment of coronary stenosis. Intracoronary scaffolding devices are needed to prevent acute vessel occlusion, to scaffold intimal tissue flaps, and to optimize vessel caliber. 7,8,37-39 The scaffolding function should last at least a few months to reduce the restenosis phenomenon associated with constrictive remodelling. 9,10,40-42 BRS can scaffold the vessel structures for a certain period of time, until they gradually lose their mechanical support with biodegradation and finally disappear. In addition, BRS can also be used as a vehicle to deliver antiproliferative agents to suppress neointimal hyperplasia, the other main contributor to restenosis. Furthermore, PCI with BRS has potential advantages over current generation metallic BMS/DES technology. These include potential reductions in adverse events such as stent/ scaffold thrombosis, as after biodegradation there would potentially be no triggers for thrombosis, such as uncovered stent struts or drug polymers that can persist long-term. The absence of these foreign materials may also reduce the requirements for long-term dual antiplatelet therapy, resulting in the potential reduction of associated bleeding complications. Physiologically, the absence of a rigid metallic cage can facilitate the restoration of the vessel vasomotor tone, adaptive shear stress, late luminal enlargement and beneficial late expansive remodeling. In the long-term, BRS will potentially not hamper future treatment options such as PCI, coronary artery bypass grafting or pharmacologically induced plaque regression. The excessive use of metallic stents in coronary vessels may interfere with reinterventional techniques in previously treated lesions, whilst BRS will potentially not interfere with such repeat procedures such as coronary bypass grafting. BRS may also be suitable for vascular anatomy where scaffolds are prone to crushing and fractures, as seen in the femoral or tibial arteries. 43 Furthermore, BRS can obviate some of the other problems associated with use of permanent metallic stents such as the covering of side branches. BRS also appears to be compatible with noninvasive imaging such as CT angiography or MRI. 5, 44 Finally, BRS can potentially help eliminate the concerns that some patients frequently have of the thought of having a 'a permanent implant in their bodies for the rest of their lives'. 45 
Development of BRS
The first experimental studies using a nonbiodegradable polyethylene-terephthalate braided mesh stents in porcine animal models were published by our group in 1992. 46 In 1996, our group, in collaboration with the Mayo and Cleveland Clinics, 47 reported the negative consequences of implantation of the Wiktor stent covered with 5 different types of biodegradable polymers (polyglycolic acid/polylactic acid copolymer: PGLA, polycaprolactone: PCL, polyhydroxy-butyrate/-valerate copolymer: PHBV, polyorthoester: POE and polyethyleneoxide/polybutylene terephthalate: PEO/PBTP) in porcine coronary arteries. These all resulted in marked inflammation and lead to significant neointimal hyperplasia and/or thrombus formation. Subsequently, Lincoff et al 48 demonstrated that in a porcine model, a stent coated with high-molecularweight poly-L-lactic acid (PLLA 321 kD) was well tolerated and effective, whilst a stent coated with low-molecular-weight PLLA (approximately 80 kD) was associated with an intense inflammatory neointimal response. The authors also proved the 
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feasibility of drug-elution from the PLLA polymer, although no suppression of neointimal hyperplasia was reported at that time.
Yamawaki et al 49 reported that in a porcine model, the fully biodegradable PLLA stent with tyrosine kinase inhibitor effectively suppressed proliferative stimuli caused by balloon injury. These pioneering experiments, with a high-molecular-weight PLLA, further supported the subsequent investigations in humans. However, despite the impressive results of these early stents, the technology failed to develop. This was primarily due to an inability to manufacture an ideal polymer that could limit inflammation and restenosis, and secondarily due to the growing interest in metallic DES.
The current generation BRS are composed of either a polymer or a metallic alloy. Numerous different polymers are available, each with a different chemical composition, and subsequent bioabsorption time ( Table 1) . The most frequently used polymer in the current generation of BDS is PLLA, which is already used in numerous clinical items, such as resorbable sutures, soft tissue implants, orthopedic implants, and dialysis media.
Bioresorption Process of PLLA
The PLLA is metabolized via the Krebs cycle over a period of approximately 12-18 months, into carbon dioxide and water (Figure 1) . From a chemical standpoint, it is considered that resorbable implants undergo 5 stages of bioresorption, which are not discrete and can overlap. 50, 51 The first stage is hydration of the polymer. After implantation of the polymeric resorbable device, the polymers begin to absorb water from the surrounding tissue. The second phase is depolymerization by hydrolysis. This is firstly observed by a reduction of molecular weight. The loss of mass (third stage) occurs when the implant no longer has cohesive strength and the polymer starts to fragment into segments of low-molecular-weight polymer. Subsequently, radial strength reduces, caused by the scission of amorphous tie chains linking the crystalline regions. At this time, cracks and structural discontinuities are normal and entirely expected, since the device is designed to degrade and be physiologically processed over time. Finally, the polymer chains that have been hydrolyzed to sufficiently short lengths, are now more hydrophilic (and hence more soluble in an aqueous environment) and are able to diffuse out of the device and be resorbed by the body (Figure 1) . The fourth phase is assimilation or dissolution of the monomer. Phagocytosis can assimilate small particles and can lead to soluble monomeric anions. Lastly, the soluble monomer (eg, L-lactate) is changed into pyruvate, which eventually ONUMA Y et al. Adapted from Garg et al. 81 mo, months; y, years.
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enters the Krebs energy cycle and is further converted into carbon dioxide and water. These final products are excreted from the body through the kidneys or lungs with the resultant complete bioresorption of the implant. 52 Due to the described properties of semicrystalline polymers, these are predominantly used for the purposes of mechanical support (ie, the scaffold), whereas amorphous polymers allow a more uniform dispersion of the drug, and are therefore preferably used in controlled drug release systems (eg, coating of the bioresorbable vascular scaffold [BVS] system).
Currently Available BRS
As of present, only one BRS has C.E. mark for peripheral use and none has US FDA approval. However, numerous scaffolds are currently undergoing preclinical and clinical trials, as summarized in Table 2 , and are described in detail below.
Polymeric Scaffolds
The Pioneering Igaki-Tamai Stent The nondrug-eluting Igaki-Tamai PLLA coronary stent was the first fully BRS to undergo evaluation in humans. This device degraded over a 18-24-month period and was mounted on a standard angioplasty balloon. Rather uniquely, heat was required to allow self-expansion of both the device and the angioplasty balloon. The initial self-expansion occurred following the use of heated contrast (up to 70°C) in the delivery balloon, whilst the final self-expansion of the stent occurred at 37°C in the 20-30 min after stent deployment (Figure 2) .
The FIM study of the Igaki-Tamai stent (15 patients, 19 lesions, 25 stents), demonstrated no MACE or ST events within 30 days, and one repeat PCI at 6 months follow-up. Encouragingly, the loss index (late loss/acute gain) was 0.48, which was comparable to BMS, and demonstrated for the first time that BRS did not induce excessive neointimal hyperplasia. Furthermore, intravascular ultrasound (IVUS) imaging demonstrated no significant stent recoil at day one, and as expected from the properties of PLLA, continued stent expansion was observed in the first 3 months of follow-up. The mean stent cross sectional area increased from 7.42± 1.51 mm 2 at baseline to 8.18±2.42 mm 2 (P=0.086) at 3 months, and 8.13±2.52 mm 2 at 6 months. In 50 elective patients (63 lesions, 84 stents), favorable long-term clinical results were reported at 3-and 10-year follow-up, which currently represents the longest available evaluation of a BRS. This study demonstrated the complete absence of stent struts on IVUS at 3-year follow-up, together with a mean angiographic diameter stenosis of 25%. 
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At 10-year clinical follow-up, freedom from cardiac death, noncardiac death and MACE was 98%, 87%, and 48% respectively. 53 In the limited cases with serial angiographic follow-up, the MLD was stable: the mean MLD was 2.01 mm at 1 year whilst the MLD was 2.06 mm at 10 years. There were 2 ST events: 1 subacute event occurring at day 5 possibly due to inadequate heparinization at the time of PCI, and one very late ST event occurring in the sirolimus-eluting metallic stent, which was later implanted proximal to the previously placed Igaki-Tamai stent. In one anecdotal case, serial angiographic and OCT images of the stent struts out to 10-year follow-up are shown in Figure 2 .
Despite these impressive results, the failure of the stent to progress was primarily related to the use of heat to induce self-expansion. There were concerns that this potentially may cause necrosis of the arterial wall leading to an excessive intimal hyperplastic response or increased platelet adhesion leading to ST. 54 None of these concerns was subsequently substantiated in the initial studies, these, however, incorporated only low-risk patients. After completion of the PERSEUS study, 55 the stent became available in Europe for peripheral use, however, there are plans to review its use in coronary arteries. At present the stent has no drug elution, although preclinical studies of the polymeric stent eluting the tyrosine kinase antagonist ST 638 have shown promising results. 49 Abbott Vascular BVS The Abbot Vascular everolimuseluting bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, CA, USA) is the only drug-eluting BRS that is currently undergoing clinical trials. The BVS has a backbone of PLLA, which is subsequently coated with a thin layer of a 1:1 mixture of an amorphous matrix of poly-D, L-lactide (PDLLA) and 8.2 μg/mm of the antiproliferative drug everolimus. The PDLLA enables controlled release of everolimus, such that 80% is eluted by 30 days. Encouragingly, studies also indicated that the BVS has comparable acute vessel recoil to the EES, inferring similar initial radial strength. 56, 57 Although the scaffold is radiolucent, 2 platinum markers at each end allow easy visualization on angiography and other imaging modalities.
The first BVS device (Revision 1.0) had a strut thickness of 150 μm, a crossing profile of 1.4 mm, and consisted of circumferential out-of-phase zigzag hoops, with struts linked directly together or by thin and straight connections (Figure 3) . The stent had to be kept stored below -20°C to prevent physical aging of the polymer and to ensure device stability, which were both inconvenient and limited the shelf life to 8 weeks. The safety and feasibility of this BVS implant was Post procedurally, some struts were found to overhang the ostium of the side branch. At 6 months, the endoluminal lining was corrugated, with struts at the ostium of the side branch being covered by neointimal tissue. At 24 months, most struts were no longer detectable, whilst the endoluminal surface was both smooth and circular. Panel D represents serial OCT images of BVS 1.1. Post procedurally, one strut was located at the site of the side branch ostium (7 o'clock); otherwise all the remaining struts were found to be well apposed and covered. At 6 months, the strut was found to be still at the ostium, but covered with some tissue. BVS, bioresorbable vascular scaffold.
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assessed in 30 low-risk patients with de novo coronary lesions enrolled in the prospective, open-label, multicenter FIM ABSORB study. 4, 5 In the study, multimodality intravascular imaging was performed using IVUS, IVUS-virtual histology (IVUSVH), palpography and OCT at 6-month and 2-year follow up. The study demonstrated the clinical safety of the BVS, with only one ischemic driven major adverse event (nonQ wave myocardial infarction (MI)) at 6 months, and no further MACE events being reported in the subsequent 42-month follow up. Of note, no ST were observed out to 4 years' follow-up. 4,5,58 Angiographic follow-up at 6 months demonstrated a late loss of 0.44 mm, which although comparable to values from the early DES studies, and somewhat lower than historical values for BMS (>0.8 mm), is still notably higher than that observed with the Xience V EES (0.11 mm). 59,60 The 6-month late loss represented a combination of neointimal hyperplasia, which was comparable to that observed with the metallic EES and a reduction in scaffold area, which occurred as a consequence of a combination of late scaffold shrinkage and nonuniform vessel support. Late scaffold shrinkage, which occurs as a consequence of the loss of radial strength with bioresorption, represents a new phenomenon that has not been observed with nonabsorbable metallic stents.
The results from multimodality imaging during follow-up helped to confirm the bioresorption of the devices. One of the major findings was a reduction in the number of apparent struts by OCT over time; the total number of apparent struts decreased by 35% over 2 years. Furthermore, the following findings support the occurrence of bioresorption: (1) the reduction in hyperechogenicity; (2) the significant increase in strain pattern on palpography; (3) the change in plaque composition on IVUSVH, and (4) the return of vasoactivity following administration of methylergometrine maleate or acetylcholine. Although all imaging studies (IVUS echogenicity, VH and OCT) suggested a certain degree of bioabsorption, this remains speculative as no comparison of the intracoronary images to histology is available. Recently, a preclinical porcine study of OCT with histology and gel-permeate chromatography showed that visible struts by OCT at 2 years were compatible with completely bioresorbed struts as demonstrated by chromatography. Also shown was that the struts that were not visible by OCT corresponded to the completion of assimilation of the struts within the surrounding tissue. 61 Therefore, in humans, the bioresorption can be completed before 2 years, even when nearly two-thirds (66%) of the struts are still visible with OCT.
The late scaffold shrinkage at 6 months seen in the ABSORB cohort A lead to important design modifications to the device. The second-generation device, Revision 1.1, utilizes the same polymer; however, a change in the manufacturing process has been made in order to maintain the mechanical integrity of the device up to 6 months. The new design has inphase zigzag hoops linked by bridges, which allow for a more consistent drug application and, as recently confirmed by OCT, more uniform strut distribution and vessel wall support (Figure 3) . 62 From a practical perspective, the stent can now be stored at room temperature. The device is currently being assessed in the recently enrolled 101 patient Cohort B ABSORB trial. Forty-five patients underwent angiographic follow-up at 6 months and will have a repeat angiography at 2 years, whilst the remaining 56 patients will undergo invasive imaging at 1 and 3 years. Currently, data from the 6-month follow-up of the first cohort is available: the late lumen loss amounts to 0.19±0.18 mm with a relative decrease in minimal luminal area of 5.4% on IVUS. 63 The late loss was considerably lower than that seen with the Revision 1.0, and similar to that commonly associated with metallic DES. Furthermore, the late strut shrinkage, which contributed to the lumen loss of Revision 1.0 device, was almost eliminated: the reduction of scaffold area was only 2.90% with IVUS and -1.9% with OCT. Unlike the first generation of BVS 1.0, the backscattering of the polymeric struts did not decrease over time, which suggests a more delayed loss of mechanical integrity compared with the BVS 1.0. Finally, clinical event rates were low with only one MI and TLR; of note was that there were no ST events according to the protocol or ARC definitions. Longer-term follow-up is ongoing. Also in progress and currently recruiting patients, is the ABSORB EXTEND multicenter single arm study, which aims to recruit approximately 1,000 patients from 50 centers worldwide. In the pipeline for the future is the pivotal noninferiority trial of the BVS vs. a metallic DES.
The REVA Stent, a Poly (Iodinated DesaminotyrosylTyrosine Ethyl Ester) Carbonate Stent The REVA stent (REVA Medical, Inc, San Diego, CA, USA) is a poly (iodinated desaminotyrosyl-tyrosine ethyl ester) carbonate stent that degrades into water, carbon dioxide, and ethanol, leaving iodinated-desaminotyrosinetyrosine, which is absorbed and excreted from the body (Figure 4) . The iodination of the desamino-tyrosine ring within the device makes it radioopaque. The stent has a resorption time of approximately 36 months. The device, however, lacked an antiproliferative drug coating. The first version had a slide and locking design that provided both flexibility and strength; this eliminated hinge points and consequently minimized the polymer strain by over 75%, thereby preventing deformation and weakening of the polymer during stent deployment. Following stent deployment, the locking mechanism maintains the acute lumen gain, and provides additional support to the stent during vessel remodeling. Benchwork data have indicated that the acute stent recoil is minimal, and the radial force of the device is comparable to a BMS. 64 Following successful preclinical trials, 27 patients with de novo lesions were enrolled in the RESORB FIM study. The study demonstrated good acute reduction in diameter stenosis following stent deployment, together with minimal vessel shrinkage at follow-up. However, focal mechanical failures driven by polymer embrittlement led to a higher than anticipated rate of TLR (66.7%) between 4 and 6 months' follow-up. Interestingly the degree of neointimal hyperplasia was similar to a BMS. 65 A redesign of the stent has ensued resulting in the secondgeneration ReZolve™ stent. This stent has a more robust polymer, a spiral 'slide and lock' mechanism to improve clinical performance, and a coating of sirolimus. The sirolimus elution is such that 80% is eluted by 30 days, and 95% by 90 days. Successful preclinical trials have been performed, and clinical trials are anticipated in 2011.
IDEAL Poly (Anhydride Ester) Salicylic Acid Stent The 8F compatible, balloon expandable radio-opaque IDEAL BRS (Bioabsorbable Therapeutics, Inc. Menlo Park, CA, USA) is unique in that its backbone consists of poly-anhydride ester together with salicylic acid, and an 8.3 μg/mm coating of sirolimus ( Figure 5 ). This combination ensures that the stent is able to provide both antiproliferative and antiinflammatory properties. On release, salicylic acid is absorbed into the surrounding vessel wall, and this is likely to account for the reduction in inflammation seen with this polymer, when compared to a BMS or Cypher ® SES. Sirolimus, which is present as a surface area dosage of approximately 25% of ONUMA Y et al. 
a conventional Cypher stent, is eluted over 30 days, whilst complete stent degradation occurs over 12 months. The stent's radial strength at implantation is significantly greater than either a BMS or Cypher stent; however, this decreases with bioabsorption, such that by approximately 60 days it is equal to the Cypher stent.
The 12-month follow-up of 11 patients enrolled in the FIM Whisper study was completed in July 2009. Preliminary results confirmed the stent's safety and radial strength, with no evidence of acute or chronic recoil. However, insufficient neointimal suppression was noted. 66 This is likely to be a consequence of the rapid elution of sirolimus coupled with an inadequate initial drug dosage.
A second-generation stent has been developed, with a higher dose of sirolimus, and a slower drug release pattern. Furthermore, the stent design has been optimized, which has resulted in a reduced crossing profile (6F compatible), and thinner struts (175 μm). Although the program was on hold in early 2009, the program will resume later in 2010 and the results of preclinical porcine coronary implants and a FIM study are anticipated in 2011.
Other Poly-L-Lactide BRS Arterial Remodeling Technologies (A.R.T, Noisy le Roi, France), Tissue Gen (Dallas, TX, USA), Elixir Medical (Sunnyvale, CA, USA), OrbusNeich (Fort Lauderdale, FL, USA); Amaranth are developing PLLA BDS; however, these stents have yet to progress beyond preclinical studies to date.
Metallic Stent Technology
Biodegradable Metallic Stent Technology (AMS-1) The balloon-expandable AMS-1 BRS (Biotronik, Berlin, Germany) is composed of 93% magnesium (approximate weight of 3.0× 10 mm is 3 mg) and 7% rare earth metals (Figure 6) . The BRS has a high mechanical strength and has other notable properties, which make it comparable to stainless steel stents, such as low elastic recoil (<8%), a high collapse pressure (0.8 bar) and minimal shortening after inflation (<5%). 6 Preclinical assessment indicated that the AMS-1 was rapidly endothelialized, with magnesium degrading within 60 days into inorganic salts with little associated inflammatory response. 67, 68 Furthermore, the negative charge that the degradation produces ensures that the stent is hypothrombogenic.
The PROGRESS AMS study was a multicenter, nonrandomized, prospective study, assessing the efficacy and safety of the AMS-1 stent in 63 patients (71 stents) with single de novo lesions. At 12-month follow-up, there were no deaths, MI or ST thus confirming the stent's safety; in addition, there was also return of vessel vasoreactivity. The rate of MACE (a composite of cardiac death, nonfatal MI, and clinically driven TLR) was 23.8% and 26.7% at 4 and 12 months' follow-up, with a disappointing high rate of TLR (both clinically and nonclinically driven) of 39.7% at 4-month and 45.0% at 12-month follow-up. 6 Additional data from both IVUS and QCA indicated that the in-stent late loss of 1.08 mm at 4 months was the result of the stent having a lower initial radial force compared to a conventional metallic stent, with the loss of this radial force being a consequence of early, rapid AMS-1 stent degradation. Other factors contributing to the luminal loss seen at follow-up were thickening of extra stent tissue (13.5%), and neointimal formation (41%). 6 Reassuringly, angiography and IVUS at long-term followup in 8 patients who did not experience an event at 4 months has shown no evidence of either later recoil or late development of neointima. In fact, in some patients evidence of neointimal regression, and/or an increase in vessel and lumen volume, was seen. 69 Of note is that the AMS stent has been proven to be MRI-compatible 44 and furthermore, the vasodilatory function of the vessel after nitroglycerin injection was restored in the treated segment at follow-up. 68 Importantly, the results from this initial study have been utilized to improve the stent's design. Modifications have centered on prolonging stent degradation time, and enabling drug elution, thereby reducing restenosis that was partly due to negative remodeling, and partly due to an excessive healing response. The new generations of stents comprise the AMS-2 and AMS-3. The AMS-2 stent uses a different magnesium alloy, resulting in the stent having a higher collapse pressure, and also a slower degradation time. Furthermore, there has been a reduction in the strut thickness from 165 μm 
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to 120 μm, an alteration to the stent's surface and, to improve radial strength, a change in the cross-sectional shape of the strut, from a rectangular to a square design. These changes appear to have had the desired effects in initial preclinical trials. 68 The AMS-3 stent (DREAMS = Drug Eluting AMS) is a modification of the AMS-2 stent, and is designed with the aim of reducing neointimal hyperplasia by incorporating a bioresorbable matrix for the controlled release of an antiproliferative drug. The drug, and its release kinetics, are under investigation; however, the stent will be assessed in the BIOSOLVE-I FIM study planned for late 2010.
Iron-Stent Technology Iron was the first metal to be considered for use in a BRS, and so far, only preclinical studies have been performed. 70, 71 To our knowledge, no further preclinical and clinical investigation have been conducted.
Future Perspective
The optimal duration of the scaffolding needs to be further elucidated. With the AMS I magnesium stent and BVS 1.0 scaffolds, late scaffold shrinkage was one of the major contributors to luminal loss. In a previous study 40 with serial IVUS imaging after angioplasty or directional coronary atherectomy, evidence of positive remodeling occurred early after the procedure up to 1 month, whilst the negative remodeling (eg, decrease in external elastic lamina) occurred from 1 to 6 months. This suggests that the need to prevent negative remodeling is necessary for a period of up to 6 months. This could potentially be achieved by tuning the biodegradation speed by changing the molecular weight of the polymer, improving the manufacturing process or the strut design. So far, the BRS technologies, without drug elution, such as REVA and AMS-I, have been associated with high TLR rates. More specifically, in the AMS-I trial, 45% of late luminal reduction was attributed to neointimal hyperplasia at 6 months. 6 These results suggest that the elution of antiproliferative agents may be indispensable to make the BRS clinically applicable and efficient at medium-term follow-up.
The clinical advantages of BRS technology over the currently available DES require further investigations. Both BVS and Mg stents have demonstrated the recovery of the responsiveness of the treated vessel to vasoactive agents such as nitroglycerin. The restoration of vasomotion can indirectly stand for vessel healing; however, it is still unclear what the real clinical advantages of this phenomenon are. A number of studies using metallic DES have reported abnormal vasomotion in the segment distal to the DES. This abnormality may restrict the distal flow and therefore predispose it to the occurrence of late stent thrombosis; however, the clinical consequences of these findings are still not clear, and require further investigation. 72 In patients with early atherosclerosis, the presence of abnormal endothelial function has been shown to be associated with poorer outcomes or more frequent angina. 73, 74 Larger studies with specific endpoints such as anginal status, functional exercise testing or fractional flow reserve, 75-77 radioisotopic investigation of flow and myocardial metabolism may be necessary. Similarly, the feasibility of MSCT/MRI to assess scaffolded segments, which have been utilized in the initial clinical trials such as PROGRESS AMS or ABSORB trials, requires further investigation. 78 A potential "new enemy" of this new technology is strut fracture. Unlike metallic stents, the polymeric devices have inherent limits of expansion and can break as a result of overdilatation. In an anecdotal case from the ABSORB cohort A, a 3.0-mm scaffold was overexpanded with a 3.5-mm balloon, which resulted in strut fracture as documented with OCT. 58 This patient underwent TLR despite an angiographically nonsignificant stenosis by QCA (%DS of 42%). The clinical significance of such a case, only evidenced by OCT, needs to be further elucidated, but undoubtedly stent fracture should be avoided by respecting the nominal size of the scaffold.
Another point of discussion is whether metallic stents with thin struts covered by a thin biodegradable polymer or metallic DES without polymer can succeed in minimizing stent thrombosis. So far the evidence shows that late stent thrombosis can occur with BMS. 21, 79 Considering the high mortality associated with stent thrombosis, our aim should be to eradicate this complication. Theoretically, the BRS technology appears closer to achieving this goal, in addition to the elimination of the deleterious caging effects of the permanent metallic endoluminal prosthesis.
In conventional metallic stents, the essential components were platform, coating and drug. When it comes to BRS polymeric stents, even with the same PLLA and design, the speed of biodegradation/bioresorption can be different according to of the manufacturing process of PLLA. For example, molecular weight can influence the degree of inflammation, as shown in a previous preclinical study. 48 Although the safety of PLLA is inferred from other medical applications such as orthopedics, orbital floor defects, and spinal surgery, each scaffolding device implanted in the coronary circulation still needs to be tested in terms of biocompatibility.
Conclusion
The currently available DES have demonstrated their ability to provide permanent scaffolding and to prevent restenosis; however, safety concerns have lead to improvements in conventional DES with the use of novel more biocompatible polymers. In addition, they have also provided the impetus for the development of bioresorbable scaffolds. Currently, the technology is still in its infancy; however, the return of normal vascular function following bioresorption has lead to the coining of a new phrase, "vascular restoration therapy". This therapy is an exciting development, and certainly worthy of the accolade of being the 4th revolution in interventional cardiology.
